U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2003
---------------------------------
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period ended to
--------------- -----------------
Commission File Number: 333-45241
ELITE PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 22-3542636
- ------------------------------- -----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
165 Ludlow Avenue, Northvale, New Jersey 07647
- ---------------------------------------- -------------------------------
(Address of principal executive offices) (Zip Code)
(201) 750-2646
----------------------------------------------------
(Registrant's telephone number, including area code)
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13 or 15 (d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court.
Yes [ ] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of the common stock, $.01 par value,
as of November 8, 2003: 10,559,426.
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
INDEX
Page No.
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Consolidated Balance Sheets as of September 30, 2003
(unaudited) and March 31, 2003 1 - 2
Consolidated Statements of Operations for the three
and six months ended September 30, 2003 and
September 30, 2002 (unaudited) 3
Consolidated Statement of Changes in Stockholders' Equity
for the six months ended September 30, 2003 (unaudited) 4
Consolidated Statements of Cash Flows for the six months
ended September 30, 2003 and September 30, 2002 (unaudited) 5
Notes 6 - 14
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS 15 - 19
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 20
PART II OTHER INFORMATION 20 - 21
Item 5 Other Information
Item 6 Exhibits and Reports on Form 8-K
SIGNATURES 22 - 26
EXHIBITS
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
ASSETS
September 30, March 31,
2003 2003
------------ ------------
(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents $ 1,372,688 $ 3,264,081
Accrued interest receivable -- 4,681
Restricted cash 29,293 99,380
Prepaid expenses and other current assets 46,887 132,092
------------ ------------
Total current assets 1,448,868 3,500,234
------------ ------------
PROPERTY AND EQUIPMENT, net of accumulated
depreciation and amortization 4,228,703 4,390,553
------------ ------------
INTANGIBLE ASSETS - net of accumulated amortization 94,072 104,842
------------ ------------
OTHER ASSETS:
Restricted cash - Debt Service Reserve 300,000 300,000
Restricted cash - Note payable 250,000 250,000
EDA bond offering costs, net of accumulated amortization
of $54,227 and $47,627, respectively 143,993 150,593
------------ ------------
Total other assets 693,993 700,593
------------ ------------
Total assets $ 6,465,636 $ 8,696,222
============ ============
The accompanying notes are an integral part of the
consolidated financial statements.
-1-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' EQUITY
September 30, March 31,
2003 2003
------------ ------------
(Unaudited)
CURRENT LIABILITIES:
Current portion - Note payable $ 75,000 $ 75,000
Current portion of EDA bonds 150,000 140,000
Accounts payable and accrued expenses 622,478 334,721
------------ ------------
Total current liabilities 847,478 549,721
------------ ------------
LONG TERM LIABILITIES:
Note payable - net of current portion 187,500 225,000
EDA bonds - net of current portion 2,345,000 2,495,000
------------ ------------
Total long-term liabilities 2,532,500 2,720,000
------------ ------------
Total liabilities 3,379,978 3,269,721
------------ ------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock - $.01 par value;
Authorized - 25,000,000 shares
Issued and outstanding - 10,559,426 and 10,544,426 shares,
Respectively 105,594 105,444
Additional paid-in capital 35,472,171 34,218,832
Accumulated deficit (32,185,266) (28,590,934)
------------ ------------
3,392,499 5,733,342
Cost of 100,000 shares of common stock held by the Company (306,841) (306,841)
------------ ------------
Total stockholders' equity 3,085,658 5,426,501
------------ ------------
Total liabilities and stockholder's equity $ 6,465,636 $ 8,696,222
============ ============
The accompanying notes are an integral part of the
consolidated financial statements.
-2-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
---------------------------- ----------------------------
2003 2002 2003 2002
------------ ------------ ------------ ------------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
REVENUES:
Research and Development $ -- $ 215,000 $ -- $ 215,000
Product Formulation Revenues -- 82,799 -- 187,810
------------ ------------ ------------ ------------
Total revenues -- 297,799 -- 402,810
------------ ------------ ------------ ------------
COST OF OPERATIONS:
Research and development 456,583 460,221 944,065 893,481
General and administrative 735,503 623,462 1,149,059 847,022
Depreciation and amortization 89,610 78,210 179,220 156,420
------------ ------------ ------------ ------------
1,281,696 1,161,893 2,272,344 1,896,923
------------ ------------ ------------ ------------
LOSS FROM OPERATIONS (1,281,696) (864,094) (2,272,344) (1,494,113)
------------ ------------ ------------ ------------
OTHER INCOME (EXPENSES):
Interest income 4,800 26,753 10,185 62,718
Interest expense (54,176) (62,813) (107,684) (116,385)
Equity in loss of Joint Venture -- (67,429) -- (186,379)
Charge relating to issuance of stock options (48,682) -- (1,051,165) --
Charge relating to warrant exchange offer (172,324) -- (172,324) --
------------ ------------ ------------ ------------
(270,382) (103,489) (1,320,988) (240,046)
------------ ------------ ------------ ------------
LOSS BEFORE PROVISION FOR INCOME TAXES (1,552,078) (967,583) (3,593,332) (1,734,159)
------------ ------------ ------------ ------------
PROVISION FOR INCOME TAXES 1,000 -- 1,000 400
------------ ------------ ------------ ------------
NET LOSS $ (1,553,078) $ (967,583) $ (3,594,332) $ (1,734,559)
============ ============ ============ ============
BASIC AND DILUTED LOSS PER COMMON SHARE $ (.15) $ (.10) $ (.34) $ (.18)
============ ============ ============ ============
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 10,559,426 9,728,682 10,551,967 9,727,607
============ ============ ============ ============
The accompanying notes are an integral part of the
consolidated financial statements.
-3-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited)
COMMON STOCK ADDITIONAL
--------------------------- PAID-IN TREASURY ACCUMULATED STOCKHOLDERS'
SHARES AMOUNT CAPITAL STOCK DEFICIT EQUITY
------------ ------------ ------------ ------------ ------------ ------------
BALANCE AT MARCH 31, 2003 10,544,426 $ 105,444 $ 34,218,832 $ (306,841) $(28,590,934) $ 5,426,501
(Audited)
Modification of Warrant
Exchange Offer -- -- 172,324 -- -- 172,324
Issuance of stock options -- -- 1,051,165 -- -- 1,051,165
Proceeds from exercising
stock options 15,000 150 29,850 -- -- 30,000
Net loss for six months
ended September 30, 2003 -- -- -- -- (3,594,332) (3,594,332)
------------ ------------ ------------ ------------ ------------ ------------
BALANCE AT SEPTEMBER 30, 2003 10,559,426 $ 105,594 $ 35,472,171 $ (306,841) $(32,185,266) $ 3,085,658
============ ============ ============ ============ ============ ============
The accompanying notes are an integral part of the
consolidated financial statements.
-4-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED
SEPTEMBER 30,
--------------------------
2003 2002
----------- -----------
(Unaudited) (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(3,594,332) $(1,734,559)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and Amortization 179,220 156,420
Equity in loss of Joint Venture -- 186,379
Charge related to issuance of stock options 1,051,165 --
Charge related to modification of warrant exchange offer 172,324 --
Changes in assets and liabilities:
Accounts and accrued interest receivable 4,681 (70,012)
Prepaid expenses and other current assets 85,205 17,570
Amount receivable from Joint Venture -- 442,460
Accounts payable, accrued expenses and other current liabilities 287,757 92,694
Deferred income -- 60,000
----------- -----------
NET CASH (USED IN) OPERATING ACTIVITIES (1,813,980) (849,048)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Maturity of short-term investment -- 100,000
Purchase of property and equipment -- (203,654)
Payment for deposit on property and equipment -- (123,396)
Purchase of patent -- (19,264)
Restricted cash 70,087 183,564
----------- -----------
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 70,087 (62,750)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants 30,000 65,843
Principal bank note payments (37,500) (37,500)
Principal repayments of NJEDA Bonds (140,000) (130,000)
Purchase of Treasury Stock -- (187,022)
----------- -----------
NET CASH (USED IN) FINANCING ACTIVITIES (147,500) (288,679)
----------- -----------
NET CHANGE IN CASH AND CASH EQUIVALENTS (1,891,393) (1,200,477)
CASH AND CASH EQUIVALENTS - beginning of period 3,264,081 6,852,434
----------- -----------
CASH AND CASH EQUIVALENTS - end of period $ 1,372,688 $ 5,651,957
=========== ===========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest $ 108,000 $ 116,385
Cash paid for income taxes 1,000 400
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND
FINANCING ACTIVITIES
Issuance of Preferred Stock Series B (including stock dividend payable of
$14,000 and subscription receivable of $67,000) $ -- $ 573,000
Conversion of Preferred Stock Series B to Common Stock -- (521)
Conversion of Preferred Stock to Additional Paid In Capital -- (772,479)
Subscription receivable - Elan International Services, Ltd. -- 16,636
Paydown of Amounts Due to Joint Venture -- (622,133)
Conversion of Joint Venture to Wholly-Owned Subsidiary -- 63,381
The accompanying notes are an integral part of the
consolidated financial statements.
-5-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION
---------------------
The information in this Form 10-Q includes the results of operations of
Elite Pharmaceuticals, Inc. and its consolidated subsidiaries
(collectively the "Company") including its wholly-owned subsidiary,
Elite Laboratories, Inc. ("Elite Labs"), for the three and six month
periods ended September 30, 2003 and 2002 and its wholly-owned
subsidiary, Elite Research, Inc. ("ERI"), for the three and six month
periods ended September 30, 2003. On September 30, 2002, the "Company"
acquired from Elan Corporation, plc and Elan International Services,
Ltd. (together "Elan"), Elan's 19.9% interest in Elite Research Ltd.
("ERL), a joint venture formed between the Company and Elan where the
Company's interest originally was 80.1%. Proforma results of operations
are presented as part of Note 3. On December 31, 2002, the Company
entered into an agreement of merger whereby ERL (a Bermuda corporation)
was merged into a new Delaware Corporation, ERI, a wholly owned
subsidiary of the Company. As a result of the merger, ERI became the
owner of all of the assets and liabilities of ERL. The merger was
accounted for as a tax-free reorganization. As of September 30, 2003,
the financial statements of all entities are consolidated and all
significant intercompany accounts are eliminated upon consolidation.
The accompanying unaudited consolidated financial statements have been
prepared pursuant to rules and regulations of the Securities and
Exchange Commission. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally
accepted in the United States of America for complete financial
statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair
presentation of the consolidated financial position, results of
operations and cash flows of the Company for the periods presented have
been included.
The financial results for the interim periods are not necessarily
indicative of the results to be expected for the full year or future
interim periods.
The accompanying consolidated financial statements of the Company have
been prepared in accordance with accounting principles generally
accepted for interim financial statement presentation and should be
read in conjunction with the consolidated financial statements and
notes included in the Company's annual report on Form 10-K for the year
ended March 31, 2003. There have been no changes in significant
accounting policies since March 31, 2003.
The Company does not anticipate being profitable for fiscal year 2004,
therefore a current provision for income tax was not established for
the three and six months ended September 30, 2003. Only the minimum
corporation tax liability required for state purposes is reflected.
NOTE 2 - STOCKHOLDERS' EQUITY
--------------------
Treasury Stock Transactions
---------------------------
At a special meeting of the Company's Board of Directors held on June
27, 2002, the Board authorized the Company to purchase up to 100,000
shares of its common stock in the open market no later than December
31, 2002. As of September 30, 2003, the Company had purchased 100,000
shares of common stock for total consideration of $306,841.
Joint Venture Subscription Offering
-----------------------------------
In October 2000, the Company entered into a joint development and
operating agreement with Elan Corporation, plc, and Elan International
Services, Ltd. (together "Elan") to develop products using drug
delivery technologies and expertise of both companies. This joint
venture, Elite Research, Ltd. ("ERL"), a Bermuda corporation, was
initially owned 80.1% by the Company and 19.9% by Elan. ERL was to fund
its research through capital contributions from its partners based on
the partners' respective ownership percentage.
-6-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 2 - STOCKHOLDERS' EQUITY (Continued)
--------------------
Joint Venture Subscription Offering (Continued)
-----------------------------------------------
ERL subcontracted research and development efforts to the Company, Elan
and others. It was anticipated that the Company would provide most of
the formulation and development work. The Company had commenced work
for three products.
ERL was initially capitalized with $15,000,000 which included the
issuance of 6,000 voting common shares, par value $1.00 per share, and
6,000 non-voting convertible preferred shares, par value $1.00 per
share. All of the voting shares were held by the Company, with the
non-voting convertible preferred shares held by both the Company and
Elan, being split 3,612 shares and 2,388 shares, respectively. Elite's
and Elan's respective ownership in ERL did not change during the term
of the joint venture.
While the Company initially owned 80.1% of the outstanding capital
stock (100% of the outstanding common stock) of ERL until September 30,
2002, Elan and its subsidiaries retained significant minority investor
rights that were considered "participating rights" as defined in the
Emerging Issues Task Force Consensus No. 96-16. Accordingly, the
Company did not consolidate the financial statements of ERL until
September 30, 2002 but instead accounted for its investment in ERL
under the equity method of accounting until the joint venture was
terminated, effective September 30, 2002.
During fiscal year 2001, ERL paid $15,000,000 to Elan for a license
providing ERL non-exclusive rights to use certain Elan in-process drug
delivery technologies. The Elan technology rights acquired relate to
very early stage technology that, in the opinion of management, have
not reached technological feasibility and have no future alternative
uses. Through the date of its termination, ERL had not recognized any
revenue.
During the fiscal year ended March 31, 2003, the Company consummated a
termination agreement (the "Termination Agreement") with Elan to
acquire all of Elan's interest in ERL. As further discussed in Note 3,
the joint venture was terminated effective September 30, 2002. As of
September 30, 2002, ERL had completed in-vivo (pilot clinical trial) on
the once-a-day Oxycodone product and began formulation and development
of two additional products.
Under the Termination Agreement, among other things, the Company
acquired all proprietary, development and commercial rights for the
worldwide markets for the products developed by ERL. In exchange for
the assignment, ERL agreed to pay Elan a royalty on certain revenues
that may be realized from the once-a-day Oxycodone product that has
been developed by ERL. Effective October 2002, the Company was solely
responsible to fund ERL's product development.
The Company did not pay, nor did Elan receive any cash consideration
under the Termination Agreement. Furthermore, the Company has the
exclusive rights to the proprietary, development and commercial rights
for the worldwide markets for the two other products developed by ERL.
The Company is not required to pay Elan royalties on revenues that may
be realized from these products.
The Company accounted for this acquisition by consolidating ERL as a
wholly-owned subsidiary as of September 30, 2002. Elan converted
773,000 shares of Series B Preferred Stock, according to their terms,
into 52,089 shares of the Company's common stock. This resulted in an
increase in common stock of $521 and an increase in additional paid in
capital of $772,479. As a result, the Series B Preferred Stock was
eliminated.
The acquisition resulted in the conversion of 13,756 shares of Series A
Preferred Stock into 764,221 shares of Elite's common stock in
accordance with their terms. The Company accounted for this conversion
by increasing common stock in the amount of $7,642 and by a
corresponding increase in additional paid in capital of $13,748,332. As
a result, the Series A Preferred Stock was eliminated.
-7-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 2 - STOCKHOLDERS' EQUITY (Continued)
--------------------
Joint Venture Subscription Offering (Continued)
-----------------------------------
As a result of the Termination Agreement, ERL became a wholly owned
subsidiary of the Company as of September 30, 2002. Elan retained
certain shares of common stock of Elite it had obtained in connection
with the joint venture and transferred other such shares to a
third-party.
Warrants and Options
--------------------
At September 30, 2003, Elite had outstanding 2,810,550 options with
exercise prices ranging from $2.00 to $10.00 and 733,752 warrants with
exercise prices ranging from $2.00 to $18.00.
During the year ended March 31, 2003, the Company issued 210,000
options to purchase common stock to an employee and to members of the
Board of the Directors. The options have exercise prices of $5.00 per
share and vest over three years. The options expire 10 years from the
date of their issuance.
During the three and six month periods ended September 30, 2003, the
Company issued an aggregate of 390,000 and 1,005,000 options,
respectively, to purchase common stock to employees and to a member of
the Board of Directors. The options have exercise prices between $2.01
and $5.00 per share. 600,000 options vested immediately, 105,000
options vest straight -line over three years and 300,000 options which
were granted to the Company's Chief Executive Officer will vest solely
upon consummation of a strategic transaction as defined in his option
agreement. The options expire ten years from date of issuance. The per
share weighted-average fair value of options granted during the three
and six months ended September 30, 2003, was $1.96 and $1.75,
respectively, using the Black-Scholes options pricing model with the
following weighted-average assumptions: no dividend yield; expected
volatility of 75.47%; risk-free interest rate of 4.0%; and expected
lives of ten years. The Company has taken a charge of $48,682 and
$1,051,165, respectively, for the three and six months ended September
30, 2003 which represents the fair value of the options vested,
utilizing the Black-Scholes options pricing model on each grant date.
The following table illustrates the effect on net loss and loss per
share as if the Company had applied the fair value recognition
provisions of SFAS No. 123 to all outstanding and unvested awards in
each period presented:
Three Months Ended September Six Months Ended September
---------------------------- --------------------------
2003 2002 2003 2002
----------- ----------- ----------- -----------
Net loss as reported $(1,553,078) $ (967,583) $(3,594,332) $(1,734,559)
Add: Stock-based compensation
expense included in reported net loss,
net of related tax effects 48,682 -- 1,051,165 --
Deduct: Total stock-based
compensation expense determined
under fair value method for all awards
net of related tax effects (268,884) (267,663) (1,491,570) (535,326)
----------- ----------- ----------- -----------
Pro-forma net loss (1,773,280) (1,235,246) (4,034,737) (2,269,885)
Loss per share as reported (.15) (.10) (.34) (.18)
Pro-forma loss per share (.17) (.13) (.38) (.23)
-8-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 2 - STOCKHOLDERS' EQUITY (Continued)
--------------------
Class A Warrant Exchange Offer
------------------------------
On October 23, 2002, the Company entered into a Settlement Agreement
with various parties in order to end a Consent Solicitation contest and
various litigation initiated by the Company. The Settlement Agreement
provided, among other things, an agreement to commence an exchange
offer (the "Exchange Offer") to which holders of the Company's Class A
Warrants which expired on November 30, 2002 (the "Old Warrants") would
have the opportunity to exchange those warrants for new warrants (the
"New Warrants") upon payment to the Company of $.10 per share of common
stock issuable upon the exercise of the old warrants. The Company in
September 2003 amended the exchange offer to eliminate the $.10 per
share exchange fee.
The New Warrants are exercisable for the same number of shares of
common stock as the Old Warrants, have an exercise price of $5.00 per
share, will expire on November 30, 2005 and will not be transferable
except by operation of law.
The Exchange Offer is exempt from registration under applicable federal
and state securities laws. The Company has agreed to register under the
Securities Act of 1933, as amended, at its expense for resale the
shares acquired upon exercise of the New Warrants.
During the year ended March 31, 2003, the Company incurred a charge of
$242,338 relating to the Exchange Offer, which represents the fair
value of the New Warrants, net of anticipated proceeds, assuming all
Class A Warrants will be exchanged. In connection with the elimination
of the $.10 per share exchange fee, the Company incurred a charge in
the second quarter of $172,324.
-9-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 3 - JOINT VENTURE ACTIVITIES
------------------------
For the three and six months ended September 30, 2002, the Company
charged $82,799 and $187,810, respectively, to ERL representing
research and development subcontractor work performed on behalf of ERL,
which was reflected in product formulation revenues. Intercompany
profits and losses were eliminated.
For the three and six months ended September 30, 2002, ERL recognized
net losses of $84,181 and $232,682, respectively. The net losses
included $82,799 and $187,810, respectively, due to the Company for
services rendered to ERL. The Company recognized 80.1% of ERL's losses,
or $67,429 and $186,379, respectively, for the three and six months
ended September 30, 2002.
As further discussed in Note 2, the joint venture was terminated
effective September 30, 2002 and the Company now owns 100 percent of
ERL's capital stock.
The following is a condensed balance sheet of ERL on September 30, 2002
(the date of acquisition):
Current Assets
Cash $ 1,084
-----------
Total assets $ 1,084
===========
Current Liabilities
Accounts payable $ 84,597
-----------
Total liabilities 84,597
Shareholders' deficit (83,513)
-----------
$ 1,084
===========
The following are unaudited pro-forma consolidated results of
operations of ERL for the three and six months ended September 30,
2002, assuming the acquisition was completed on April 1, 2002.
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, 2002 SEPTEMBER 30, 2002
------------------ ------------------
Revenue $ 215,000 $ 215,000
Net (loss) available to common
shareholders $ (984,334) $ (1,780,862)
Net (loss) per share available to common
shareholders -
basic and diluted $ (0.10) $ (0.18)
Unaudited pro-forma data may not be indicative of the results that
would have been obtained had these events actually occurred at the
beginning of the periods presented, nor does it intend to be a
projection of future results.
-10-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 4 - COMMITMENTS AND CONTINGENCIES
-----------------------------
Litigation with Atul M. Mehta
-----------------------------
The Company had an employment agreement ("Employment Agreement") with
its former President/CEO, Dr. Atul M. Mehta ("Mehta").
On June 3, 2003, Mehta resigned from all positions that he held with
the Company, while reserving his rights under his Employment Agreement
and under common law. On July 3, 2003, Mehta instituted litigation
against the Company and one of its directors in the Superior Court of
New Jersey, alleging, among other things, the breach of his Employment
Agreement and defamation, and claiming that he is entitled to receive
his salary through June 6, 2006. His salary would total approximately
$1,000,000 through June 6, 2006.
The Company has filed counterclaims against Mehta and has filed a
motion to dismiss Mehta's claims, and, as part of that motion, sought
to compel Mehta to assign and transfer to the Company all patents in
Mehta's name which were developed during his employment with the
Company. Similarly, the director filed a motion to dismiss Mehta's
claim individually. In addition to opposing the Company's and the
director's motions, Mehta cross-moved to compel the Company to permit
him to sell 1% of his stock in the Company.
The Court has directed that oral arguments on the above motions and
cross-motions will be heard on November 3, 2003. After argument on the
motion, the Court will hold a scheduling conference to discuss
discovery in the litigation. To date, although the Company has
propounded discovery requests upon Mehta, Mehta has not responded to
the written discovery demands.
The Company believes Mehta's claims are without merit and continues to
vigorously contest this action. Prior to Mehta's resignation, a
majority of the members of the Company's Board of Directors notified
Mehta that they believed that sufficient grounds existed for the
termination of his employment for "Severe cause" pursuant to his
Employment Agreement. The failure of the Company to prevail in this
action, would have a material adverse effect on its financial condition
and results of operations.
-11-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 4 - COMMITMENTS AND CONTINGENCIES (Continued)
-----------------------------
Referral Agreement
------------------
The Company entered in January 2002 into a Referral Agreement with one
of its directors (Referring Party) whereby the Company will pay the
Referring Party a fee based upon payments received by the Company from
sales of products, development fees, licensing fees and royalties
generated as a direct result of the Referring Party identifying
customers for the Company. These amounts are to be reduced by the cost
of goods sold directly incurred in the manufacturing or development of
products as well as any direct expenses associated with these efforts.
The Referral Agreement has no expiration date. The Company committed to
pay the Referring Party a referral fee each year as follows:
Percentage of Referral Referral Base
Base From To
---- ---- --
5% $ 0 $ 1,000,000
4% 1,000,000 2,000,000
3% 2,000,000 3,000,000
2% 3,000,000 4,000,000
1% 4,000,000 5,000,000
As of September 30, 2003, no payments were required to be made under
this agreement.
Collaborative Agreements
------------------------
The Company entered in June 2001 into two separate and distinct
development and license agreements with another pharmaceutical company
("partner"). The Company is developing two drug compounds for the
partner in exchange for certain payments and royalties. The Company
also reserves the right to manufacture the compounds. The Company
received $250,000 and $300,000, respectively, under these two
agreements, all of which were earned as of March 31, 2002. The Company
is currently proceeding with development and formulation for both
products as specified in the development agreements. No amount was
earned during the three and six months ended September 30, 2003. During
the three months ended September 30, 2002 the Company earned $75,000,
for additional development and formulation for both products, but
nothing thereafter.
On September 13, 2002, the Company, entered into a manufacturing
agreement with Ethypharm S.A. ("Ethypharm"). Under the terms of this
agreement, the Company initiated the manufacturing of a new
prescription drug product for Ethypharm. The Company received an
upfront manufacturing fee for the first phase of the technology
transfer and billed an additional amount upon the completion of the
first phase of manufacturing. The Company is entitled to receive
additional fees in advance for the final phase of the manufacturing. In
addition, if and when FDA approval is obtained and if requested by
Ethypharm, the Company will manufacture commercial batches of the
product on terms to be agreed upon.
As of September 30, 2003, the Company billed and earned revenues of
$280,000, under the Ethypharm agreement, none of which was earned
during the six months ended September 30, 2003 and $200,000 of which
was billed and earned during the six months ended September 30, 2002,
in accordance with the substantive milestone method of revenue
recognition. Under this method, the milestone payments are considered
to be payments received for the accomplishment of a discrete,
substantive earnings event. Accordingly, the non-refundable milestone
payments are recognized in full when the milestone is achieved.
-12-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 4 - COMMITMENTS AND CONTINGENCIES (Continued)
-----------------------------
Contingencies
-------------
Elite Labs is the plaintiff in a civil action brought in the Superior
Court of New Jersey on November 20, 2000 against three parties to
recover damages in an unspecified amount based on the alleged failure
of the defendants to perform properly and complete certain
pharmaceutical tests and studies for which Elite Labs paid
approximately $950,000.
The defendants brought a counterclaim of approximately $250,000
allegedly due for services rendered to Elite Labs by the defendants for
the completion of bioequivalency studies and for the storage of
laboratory samples. Elite Labs is vigorously contesting the
counterclaim.
The action and counterclaim are proceeding in pretrial discovery under
a Case Management Order entered by the court. All discovery was
completed by September 15, 2003. Settlement discussions are currently
being conducted. If such action or counterclaim is in favor of the
defendants, the recovery, if any, is not expected to have a material
effect on the Company's financial condition or results of operations.
Legal counsel is unable to predict the outcome of these actions.
Accordingly, no provision for liability, if any, has been provided in
the accompanying consolidated financial statements.
Employment Agreement
--------------------
On July 23, 2003, the Company entered into an employment agreement with
its new Chief Executive Officer, Bernard Berk. The initial term of this
agreement is three years. Pursuant to this agreement:
- Mr. Berk is entitled to receive a base salary of $200,000 per
annum, subject to increase to $330,140 if and when the Company
consummates a Strategic Transaction (as defined in the employment
agreement);
- The Company confirmed its grant to Mr. Berk on June 3, 2003 of
options to purchase 300,000 shares of the Company's common stock at
$2.01 per share. All of these options are vested.
- The Company granted Mr. Berk options to purchase an additional
300,000 shares of its common stock, with an exercise price equal to
$2.15, the closing price of the Company's common stock on the date of
grant. These options will vest solely upon consummation of a Strategic
Transaction.
- Mr. Berk will be appointed as a director of the Company if he is
serving as its Chief Executive Officer following the consummation of a
Strategic Transaction.
- Mr. Berk will be entitled to receive severance in accordance with
the employment agreement if he is terminated without cause or because
of his death or permanent disability or if he terminates his employment
for good reason. The severance will be payable in accordance with the
terms of his employment agreement.
-13-
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
(UNAUDITED)
NOTE 5 - POSSIBLE MERGER
---------------
On August 6, 2003, the Board of Directors authorized the Company's
management to negotiate a merger agreement with Nostrum
Pharmaceuticals, Inc. ("Nostrum"), a privately-held company engaged in
the development of drug delivery products, whereby Nostrum would be
merged into a new subsidiary of the Company in exchange for
approximately 32,000,000 shares of the Company's common stock and
options to acquire substantial additional shares of the Company's
common stock on terms to be agreed upon by the parties.
The proposed merger agreement is subject to the approval of the Board
of Directors of the Company and will provide, as conditions to the
merger, that the merger be approved by the Company's shareholders, that
the Company's Board of Directors be expanded with certain members
designated by former Nostrum shareholders, and that the Company
maintain a designated amount of working capital as of the effective
date and other customary closing conditions.
No assurance can be given that a definitive merger agreement will be
executed or that, if executed, the conditions to the merger will be
satisfied. The actual number of shares of the Company's common stock,
and options exercisable for the Company's common stock, issuable upon
closing of the proposed transaction will be determined in the
definitive merger agreement, as may be approved, and may vary from the
amounts set forth above.
-14-
ELITE PHARMACEUTICALS, INC.
PART I. ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2003 COMPARED TO
THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2002
The following discussion and analysis should be read in conjunction
with the Consolidated Financial Statements, the related Notes to Consolidated
Financial Statements and Management's Discussion and Analysis of Financial
Condition and Results of Operations included in the Company's Annual Report on
Form 10-K for the fiscal year ended March 31, 2003 (the "10-K") and the
Unaudited Consolidated Financial Statements and related Notes to Consolidated
Financial Statements included in Item 1 of Part I of this Quarterly Report on
Form 10-Q.
The Company has included in this Quarterly Report certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 concerning the Company's business, operations and
financial condition. "Forward-looking statements" consist of all non-historical
information, and the analysis of historical information, including the
references in this Quarterly Report to future revenue growth, future expense
growth, future credit exposure, EBITDA, future profitability, anticipated cash
resources, anticipated capital expenditures, capital requirements, and the
Company's plans for future periods. In addition, the words "could", "expects",
"anticipates", "objective", "plan", "may affect", "may depend", "believes",
"estimates", "projects" and similar words and phrases are also intended to
identify such forward-looking statements.
Actual results could differ materially from those projected in the
Company's forward-looking statements due to numerous known and unknown risks and
uncertainties, including, among other things, unanticipated technological
difficulties, the volatile and competitive environment for drug delivery
products, changes in domestic and foreign economic, market and regulatory
conditions, the inherent uncertainty of financial estimates and projections, the
difficulties of integrating businesses which were previously operated as
stand-alone units, the creditworthiness of the Company's customers, the
uncertainties involved in certain legal proceedings, instabilities arising from
terrorist actions and responses thereto, and other considerations described as
"Risk Factors" in other filings by the Company with the SEC including the Form
10-K. Such factors may also cause substantial volatility in the market price of
the Company's common stock. All such forward-looking statements are current only
as of the date on which such statements were made. The Company does not
undertake any obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such statement is
made or to reflect the occurrence of unanticipated events.
Overview
The Company is involved in the development of controlled drug delivery
systems and products. Its products are in varying stages of development and
testing. In addition, from time to time, the Company has also conducted research
and development projects on behalf of other pharmaceutical companies although
these activities have generated only limited revenue to date, all prior to the
current fiscal year.
Critical Accounting Policies and Estimates
Management's discussion addresses the Company's consolidated financial
statements, which have been prepared in accordance with accounting principles
generally accepted in the United States of America. The preparation of these
financial statements requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of
contingent assets and liabilities at the date of financial statements and the
reported amounts of revenues and expenses during the reporting period. On an
ongoing basis, management evaluates its estimates and judgment, including those
related to bad debts, intangible assets, income taxes, workers compensation, and
contingencies and litigation. Management bases its estimates and judgments on
historical experience and on various other factors that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.
-15-
ELITE PHARMACEUTICALS, INC.
PART I. ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2003 COMPARED TO
THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2002
(CONTINUED)
Management believes the following critical accounting policies, among
others, affect its more significant judgments and estimates used in the
preparation of its consolidated financial statements. The Company's most
critical accounting policies include the recognition of revenue upon completion
of certain phases of projects under research and development contracts. The
Company also assesses a need for an allowance to reduce its deferred tax assets
to the amount that it believes is more likely than not to be realized. The
Company assesses the recoverability of long-lived assets and intangible assets
whenever events or changes in circumstances indicate that the carrying value of
the asset may not be recoverable. The Company assesses its exposure to current
commitments and contingencies. It should be noted that actual results may differ
from these estimates under different assumptions or conditions.
During the fiscal year ended March 31, 2003, the Company elected to
prospectively recognize the fair value of stock options granted to employees and
members of the Board of Directors, effective as of the beginning of the fiscal
year. The prospective method allowed by the Financial Accounting Standards Board
effects the Company's results of operations for the three and six-month periods
ended September 30, 2003 since 600,000 options were granted which vested
immediately and other options were granted that vest over three years. The
Company does not know the future effect of options which may be granted to
employees and members of the Board of Directors.
Results of Consolidated Operations
Three Months Ended September 30, 2003 Compared to Three Months Ended September
30, 2002
The Company had no revenues for the three months ended September 30,
2003 as compared with $297,799 over the comparable period of the prior year. For
the three months ended September 30, 2002, revenues consisted of product
formulation fees of $82,799 earned in conjunction with the Company's joint
venture with Elan Corporation ("Elan") in Elite Research, Limited ("ERL") and
research and development fees of $215,000 earned in conjunction with its
distinct development, license, and manufacturing agreements. Elan's obligation
to make payments to the Company or to ERL terminated upon the termination of the
joint venture on September 30, 2002. The absence of payments from Elan has
effected and will affect revenues for periods subsequent to September 30, 2002.
General and administrative expenses for the three months ended
September 30, 2003 were $735,503, an increase of $112,041 or 18% from the
comparable period of the prior year. The increase in general and administrative
expenses was substantially due to increases in legal fees and consulting fees,
and increases in administrative salaries partly due to business development
wages.
Research and development costs for the three months ended September 30,
2003 were $456,583, a decrease of $3,638 or less than 1% than those for the
comparable period of the prior year.
Other expenses for the three months ended September 30, 2003 were
$270,382, an increase of $166,893, or approximately 161% from the comparable
period of the prior year. The increase is due to charges of $48,682 related to
the issuance of stock options, charges of $172,324 related to the modification
of warrant exchange offer, and the reduction of $21,953 in interest income due
to lower rates and compensation balances which was partially offset by the
decrease of $67,429 in equity loss of joint venture.
-16-
ELITE PHARMACEUTICALS, INC.
PART I. ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE AND SIX MONTH PERIOD ENDED SEPTEMBER 30, 2003 COMPARED TO
THE THREE AND SIX MONTH PERIOD ENDED SEPTEMBER 30, 2002
(CONTINUED)
Three Months Ended September 30, 2003 Compared to Three Months Ended September
30, 2002 (continued)
The Company's net loss for the three months ended September 30, 2003
was $1,553,078 compared to $967,583 for the comparable period of the prior year.
The increase in the net loss was due to the lack of revenue, charges of $48,682
relating to the issuance of stock options and charges of $172,324 due to changes
in the exchange of warrants and an increase in general and administrative costs
as a result of higher legal and consulting fees.
Six Months Ended September 30, 2003 Compared to Six Months Ended September 30,
2002
The Company had no revenues for the six months ended September 30, 2003
as compared with $402,810 over the comparable period of the prior year. For the
six months ended September 30, 2002, revenues consisted of product formulation
fees of $187,810 earned in conjunction with the Company's joint venture with
Elan in ERL and research and development fees of $215,000 earned in conjunction
with its distinct development, license and manufacturing agreements. Elan's
obligation to make payments to the Company or to ERL terminated upon the
termination of the joint venture on September 30, 2002. The absence of payments
from Elan has effected and will affect revenues for the future.
General and administrative expenses for the six months ended September
30, 2003 were $1,149,059, an increase of $302,037 or 36% from the comparable
period of the prior year. The increase was substantially due to increases in
legal fees and consulting fees, and increases in administrative salaries partly
due to business development wages.
Research and development costs for the six months ended September 30,
2003 were $944,065, an increase of $50,584 or approximately 6% from the
comparable period of the prior year. Research and development costs have
increased, primarily the result of increased research and development wages,
additional biostudies, and as a result of the termination of the joint venture
as the Company is solely responsible to fund product development, which it
expects to fund from internal resources or through loans or investment by third
parties.
Other expenses for the six months ended September 30, 2003 were
$1,320,988, an increase of $1,080,942, or approximately 450% from the comparable
period of the prior year. The increase is due to charges of $1,051,165 related
to the issuance of stock options, a charge of $172,324 relating to the
modification of the warrant exchange offer, and the reduction of $52,533 in
interest income due to lower rates and compensating balances, partially offset
by a decrease of $186,379 in equity loss of the joint venture due to its
termination.
The Company's net loss for the six months ended September 30, 2003 was
$3,594,332 compared to $1,734,559 for the comparable period of the prior year.
The increase in the net loss was primarily due to the lack of revenue, charges
of $1,051,165 relating to the issuance of stock options and an increase in
general and administrative expenses.
-17-
ELITE PHARMACEUTICALS, INC.
PART I. ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2003 COMPARED TO
THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2002
(CONTINUED)
Material Changes in Financial Condition
The Company's working capital (total current assets less total current
liabilities), which was $2,950,513 as of March 31, 2003, decreased to $601,390
as of September 30, 2003. The decrease in working capital is primarily due to
the Company's net loss from operations.
The Company experienced negative cash flow from operations of
$1,813,980 for the six months ended September 30, 2003, primarily due to the
Company's net loss from operations of $3,594,332, offset by non-cash charges of
$1,402,709.
Liquidity and Capital Resources
For the six months ended September 30, 2003, the Company suffered a
negative cash flow and financed its operations primarily through the private
sale of its equity and debt securities. The Company had working capital of $.6
million at September 30, 2003 compared with $5.4 million at September 30, 2002.
Cash and cash equivalents at September 30, 2003 were $1.4 million, a decrease of
$4.3 million from the $5.7 million at September 30, 2002.
Net cash used in operating activities was $1,813,980 during the six
months ended September 30, 2003, compared to $849,048 for the six months ended
September 30, 2002. Net cash used in operating activities during the six months
ended September 30, 2003 resulted primarily from the Company's net loss of
$3,594,332, offset in part by non-cash charges of $1,402,709 and by a reduction
in accounts receivable and an increase in accrued expenses and certain non-cash
expenses. Net cash used in operating activities during the six months ended
September 30, 2002 resulted primarily from a net loss of $1,734,559, offset in
part by certain non-cash expenses.
Investing activities provided net cash of $70,087 during the six months
ended September 30, 2003 which resulted from a decrease in restricted cash. Net
cash utilized by investing activities of $62,750 during the six months ended
September 30, 2002 which resulted from the acquisition of property and
equipment, payment of a deposit thereon and the purchase of a patent, partially
offset by the maturity of short-term investments and a decrease in restricted
cash.
Financing activities utilized net cash of $147,500 during the six
months ended September 30, 2003 which resulted from the repayment of $177,500 of
indebtedness, offset partially by the sale of common stock and warrants.
Financing activities utilized net cash of $288,679 during the six months ended
September 30, 2002 primarily from the repayment of indebtedness and the purchase
of the Company's stock, offset in part by the sale of common stock and warrants.
The Company anticipates that its capital expenditures for the 12
months ending September 30, 2004 will be limited to expenditures that can be
funded entirely by development contracts that include provisions for such
funding for these expenditures. There can be no assurance that the Company will
enter into any such agreements.
-18-
ELITE PHARMACEUTICALS, INC.
PART I. ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2003 COMPARED TO
THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2002
(CONTINUED)
The Company's capital expenditures aggregated $327,050 for the
six-month period ended September 30, 2002. Such expenditures consisted primarily
of the acquisition of property and equipment necessary to support the Company's
existing operations and expected growth.
The Company has outstanding $2,495,000 in aggregate amount of bonds.
The bonds bear interest at a rate of 7.75% per annum and are due on various
dates between 2005 and thereafter. The bonds are secured by a first lien on the
Company's facility in Northvale, New Jersey. Pursuant to the terms of the bonds,
several restricted cash accounts have been established for the payment of bond
principal and interest. Bond proceeds were utilized for the refinancing of the
land and building the Company currently owns, the purchase of certain
manufacturing equipment and related building improvements and the maintenance of
a $300,000 debt service reserve. All of the restricted cash, other than the debt
service reserve, is expected to be expended within twelve months and is
therefore categorized as a current asset on the Company's consolidated balance
sheet as of September 30, 2003. Pursuant to the terms of the bond indenture
agreement pursuant to which the bonds were issued, the Company is required to
observe certain covenants, including covenants relating to the incurrence of
additional indebtedness, the granting of liens and the maintenance of certain
financial covenants. As of September 30, 2003 the Company was in compliance with
the covenants contained in the bond indenture agreement.
As a result of expenditures associated with operating the Company's
business and the joint venture termination, the Company's cash expenses have
exceeded its generated revenues for the six months ended September 30, 2003. In
order to conserve cash for the next twelve months, the Company intends to reduce
costs by reducing the number of products under active development to six.
However, while the Company anticipates having adequate capital to support its
operations through the end of the Company's current fiscal year, it will need to
raise capital and/or generate additional revenues in order to support its
operations beyond that time.
As of September 30, 2003, the Company's principal source of liquidity
was approximately $1,372,688 of cash and cash equivalents.
The Company is currently in negotiations to enter into an agreement and
plan of merger with Nostrum Pharmaceuticals, Inc., a private drug development
company, which would provide for Nostrum to become a wholly-owned subsidiary of
the Company and for the shareholders of Nostrum to be issued approximately
32,000,000 shares of Common Stock, together with options to acquire a
substantial number of additional shares of Common Stock exercisable on
satisfaction of certain conditions. The merger proposal contemplates that as one
of the conditions to its consummation, the Company's working capital be
increased to a designated amount. The Company believes that any increase in its
working capital would be funded through issuances of its equity, as to which no
assurance can be given.
-19-
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company had no investments in marketable securities as of September
30, 2003 or assets and liabilities which are denominated in a currency
other than U.S. dollars or involve commodity price risks.
PART II. OTHER INFORMATION
Item 5. OTHER INFORMATION
Employment Agreement with Bernard Berk
--------------------------------------
On July 23, 2003, the Company entered into an employment agreement with
its new Chief Executive Officer, Bernard Berk. The initial term of this
agreement is three years. Pursuant to this agreement:
- Mr. Berk is entitled to receive a base salary of $200,000 per
annum, subject to increase to $330,140 if and when the Company
consummates a Strategic Transaction (as defined in the agreement);
- The Company confirmed its grant to Mr. Berk on June 3, 2003 of
options to purchase 300,000 shares of the Company's common stock at
$2.01 per share. All of these options are vested.
- The Company granted Mr. Berk options to purchase an additional
300,000 shares of its common stock, with an exercise price of $2.15,
the closing price of the Company's common stock on the date of grant,
such options to vest solely upon consummation of a Strategic
Transaction.
- Mr. Berk will be appointed as a director of the Company if he is
serving as its Chief Executive Officer following the consummation of a
Strategic Transaction.
- Mr. Berk will be entitled to receive severance in accordance with
the agreement if he is terminated without cause, as defined, or because
of his death or permanent disability or if he terminates his employment
for good reason as defined.
Change to Class A Warrant Exchange Offer
----------------------------------------
The Company recently amended its offer to exchange its new Class C
Warrants for outstanding Class A Warrants, which expired on November
30, 2002, to eliminate the $.10 per share exchange fee.
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
31.1 Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification by Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
-20-
(b) Reports on Form 8-K.
No Reports on Form 8-K were filed during the three months ended
September 30, 2003 except that:
A Report on Form 8-K was filed on August 8, 2003 containing
responses to Items 5 and 7 with respect to the Company's press
release reporting its Board of Directors' authorization of the
Company's management to negotiate a definitive merger agreement
with Nostrum Pharmaceuticals, Inc.
A Report on Form 8-K was filed on September 23, 2003 containing
responses to Items 5 and 7 with respect to the Company's exchange
of Class C Warrants for Class A Warrants.
-21-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ELITE PHARMACEUTICALS, INC.
Date: November 13, 2003 By: /s/ BERNARD BERK
--------------------------------------------
Bernard Berk
Chief Executive Officer
(Principal Executive Officer)
Date: November 13, 2003 By: /s/ MARK I. GITTELMAN
--------------------------------------------
Mark I. Gittelman
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
-22-